Case Report

Sunitinib Induced Thrombotic Thrombocytopenic Purpura in addition to Severe Hypothyroidism: A Case Report and Review of the Literature

Imane El Dika, Deborah Mukherji, Sally Temraz, Rita Assi, and Ali Shamseddine

Department of Internal Medicine, Division of Medical Oncology, American University of Beirut Medical Center, P.O. Box 11-0236, Riad El Solh, Beirut 11072020, Lebanon

Correspondence should be addressed to Ali Shamseddine; as04@aub.edu.lb

Received 2 June 2014; Accepted 15 September 2014; Published 7 October 2014

Academic Editor: Maxwell V. Meng

Copyright © 2014 Imane El Dika et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

1. Introduction

Sunitinib is an oral multitargeting tyrosine kinase inhibitor that inhibits members of the receptor tyrosine kinases (RTK) families containing a split-kinase domain. These families include VEGF receptor (VEGFR) types 1 (FLT1), 2 (KDR), and 3 (FLT4); platelet-derived growth factor receptors A and B (PDGFRα and PDGFRβ); the stem cell factor receptor (cKIT); FMS-like tyrosine kinase 3 (FLT3); colony-stimulating factor 1 receptor (CSF-1R); and glial cell line-derived neurotrophic factor receptor [rearranged during transfection (RET)]. It is clinically approved in the treatment of pancreatic neuroendocrine tumor [1], metastatic renal cell carcinoma (mRCC) [2], and imatinib resistant metastatic gastrointestinal stromal tumor [3]. However, the broad-spectrum activity associated with this multitargeted drug confers it with a unique toxicity profile. Reported adverse events include asthenia, diarrhea, skin toxicities, hypothyroidism, cardiotoxicity, hypertension, and myelosuppression [4]. Bleeding events and tumour hemorrhages have been reported in many patients receiving sunitinib for mRCC. It ranges from epistaxis to severe life-threatening hemoptysis or pulmonary hemorrhage. The inhibitory concentration (IC\textsubscript{50}) of sunitinib is 143 for PDGFR-alpha, 75 for PDGFR-beta, 21 and 34 for VEGFR 1 and VEGFR 2, respectively [5], which is higher than IC\textsubscript{50} for other tyrosine kinase inhibitors, making sunitinib one of the most potent inhibitors of VEGFR and PDGFR.

Interestingly, fibroblast growth factor receptors, PDGFRs, VEGFRs, and their ligands have been shown to play important roles in tumor growth and angiogenesis. Inhibition of VEGF signaling through the use of antibodies or VEGFR antagonists has demonstrated the effect against tumor progression and metastasis.

Here we present the case report of a patient with metastatic renal cell carcinoma (mRCC) who developed thrombotic thrombocytopenic purpura (TTP) on sunitinib that was
completely reversible after treatment withdrawal and plasma exchange therapy.

2. Case Presentation

A 73-year-old female patient, with diagnosis of mRCC, presented with epistaxis and fatigue 28 days after being started on sunitinib 50 mg daily. Her medical history is significant for right radical nephrectomy in July 2009 for clear cell carcinoma, Fuhrman grade 4/4. In March 2012 she had left partial nephrectomy for recurrent disease. Pathology revealed clear cell carcinoma, Fuhrman grade 3/4, with negative surgical margins. In May 2013, she presented again with recurrence in the left kidney along with new right lung metastasis.

On clinical examination, she was pale and had diffuse ecchymosis with severe lower extremity edema. She had also decreased air entry at the lung bases. There were no fever and no neurological symptoms; she had no skin changes over her hands or feet and no diarrhea.

Relevant laboratory findings include a thyroid stimulating hormone (TSH) level of more than 100 μU/mL (0.27–4.20 μU/mL), hemoglobin of 8.8 g/dL (12–16 g/dL), and platelets count of 38000/mm^3 (150000–400000/mm^3). Creatinine increased to 3.2 mg/dL from baseline of 1.5 mg/dL (0.4–1.0 mg/dL) and lactate dehydrogenase (LDH) was 792 IU/L (110–265 IU/L). Her platelets count before initiating sunitinib therapy was 301000/mm^3. Her hemoglobin was 11 g/dL. TSH level was 2.3 μU/mL.

Her symptoms and cytopenia were initially thought to be due to severe hypothyroidism secondary to Sunitinib.

Sunitinib was then stopped and she was initiated on thyroid replacement hormone with supportive measures. During her hospitalization, she had systolic blood pressure readings reaching 170 mmHg, and her creatinine and proteinuria were not improving. Her platelet count reached a nadir of 12000/mm^3. A blood film inspection interestingly revealed marked schistocytes; haptoglobin was 0.08g/L (0.30–2.0); and reticulocyte count was 3.4% (0.2–2.0). Coagulation studies were normal and bone marrow evaluation was negative for malignancy.

In view of the above picture, the diagnosis of TTP was made. Plasma exchange was then started. After six sessions her blood counts values returned to normal, and creatinine level as well as TSH normalized. Platelet count and LDH level in response to plasma exchange sessions are shown in Figure 1. Sunitinib was therefore stopped definitely and the patient was advised to undergo tumor resection along with lung metastasectomy. However, she opted for best supportive care.

3. Discussion

Sunitinib is a tyrosine kinase inhibitor that targets VEGFR 2 and PDGFR-beta, which are both the major subtypes of VEGFR and PDGFR in capillary vasculature. It is hypothesized that sunitinib acts via direct anti-VEGFR and anti-PDGFR effects that result in damage of the capillary endothelium.

A number of chemotherapeutic agents have been proved to be associated with TTP-HUS, including gemcitabine, cisplatin, doxorubicin, oxaliplatin, and mitomycin C. Few cases of TMA or TTP-HUS were reported after sunitinib treatment. The pathophysiology of TTP-HUS and renal thrombotic microangiopathy (TMA) due to sunitinib is not very well understood.

Renal toxicity has been widely reported with bevacizumab, a VEGF pathway inhibition.

Hohenstein et al. [6] demonstrated in a murine model of site-specific (kidney) endothelial injury that VEGF was lost in many severely injured tubules and glomeruli (podocytes), but in parallel strongly upregulated in less severely injured tubules and glomeruli. This was associated with high platelet influx and presence of schistocytes in peripheral blood.

Frangié et al. [7] reported a case of TTP-HUS after treatment with anti-VEGF antibody bevacizumab for mRCC that recurred after use of sunitinib and required plasmapheresis. TMA and mesangiolysis were proven by renal biopsy.

Eremina et al. reported six cases for patients who developed glomerular injury in favor of TMA on treatment with bevacizumab [8]. Eremina et al. demonstrated that local reduction of VEGF within the murine kidney resulted in profound effects on the adjacent glomerular endothelium, causing significant damage to the fenestrated endothelium and microvascular injury, leading to thrombotic microangiopathy. VEGF production by podocytes seems to be required for normal functioning and maintenance of the adjacent glomerular endothelium.

Ansari and George reported a case of sunitinib induced immune-mediated thrombocytopenia [9] that was completely reversible after withdrawal of the drug and treatment by steroids and immunoglobulins. Chemotherapeutic and immunosuppressive agents typically cause thrombocytopenia by suppressing hematopoiesis. However immune-mediated thrombocytopenia is very well reported. Sunitinib has been associated with other autoimmune disorders such as hypothyroidism; therefore, the possibility of an immunologic
Table 1: Summary of cases of TTP associated with sunitinib in the literature.

<table>
<thead>
<tr>
<th>Author</th>
<th>Age/sex</th>
<th>Cancer</th>
<th>Dose/time of onset</th>
<th>Presentation</th>
<th>Treatment</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kapiteijn et al. [12]</td>
<td>54 years/female</td>
<td>GIST*</td>
<td>50 mg/day 6th cycle</td>
<td>Loss of vision, seizure, hypertension, and RPLS§</td>
<td>Withdrawal and plasma exchange</td>
<td>Recovery</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Frangié et al. [7]</td>
<td>70 years/male</td>
<td>RCC†</td>
<td>ND‡/3 weeks</td>
<td>Asthenia, hypertension, and renal insufficiency</td>
<td>Withdrawal and plasma exchange</td>
<td>Recovery</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Choi et al. [14]</td>
<td>62 years/female</td>
<td>RCC</td>
<td>50 mg/day 3 weeks</td>
<td>Hematuria, proteinuria, and hypertension</td>
<td>Withdrawal and plasma exchange</td>
<td>Recovery</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>This case</td>
<td>73 years/female</td>
<td>RCC</td>
<td>50 mg/day 4 weeks</td>
<td>Asthenia, edema, renal insufficiency, and anemia</td>
<td>Withdrawal and plasma exchange</td>
<td>Recovery</td>
</tr>
</tbody>
</table>

* Gastrointestinal stromal tumor.
† Rapidly progressing posterior leucoencephalopathy.
‡ Renal cell carcinoma.
§ Not described.

phenomenon to account for sunitinib-induced immune-mediated thrombocytopenia is quite reasonable.

Taleb et al. reported a case of sunitinib induced microangiopathic hemolytic anemia (MAHA) with a fatal outcome despite treatment with plasmapheresis, dialysis, and withdrawal of sunitinib [10]. ADAMTS-13 inhibitor assay was negative.

Costero et al. reported the first case of histologically confirmed focal segmental glomerulosclerosis in addition to TMA secondary to sunitinib treatment [11].

Kapiteijn et al. reported a case of TMA and reversible posterior leucoencephalopathy syndrome (RPLS) due to sunitinib in imatinib resistant GIST [12].

Another case of TMA after treatment with sunitinib for refractory malignant skin hidradenoma was also reported by Bollée et al. [13]. He demonstrated histological renal involvement and hypothesized that all anti-VEGF drugs may share a common risk for developing renal adverse events. In contrast to bevacizumab induced TMA, complement alternative pathway was not involved. There were glomerular subendothelial deposits of IgA and IgM, similar to bevacizumab-associated deposits.

Choi et al. [14] reported a case of TTP-HUS secondary to sunitinib for mRCC.

Table 1 summarizes the reported cases of TTP secondary to sunitinib in the literature.

In contrast to chemotherapy induced TTP-HUS, sunitinib induced TTP-HUS does not seem to be dose dependent and has a better outcome after stopping the drug and plasma exchange therapy [15]. Most sunitinib-associated adverse events are related to its mechanism of action. Although molecular basis behind each toxicity is not very well understood, inhibition of VEGF signaling seems to be behind proteinuria, hypertension, and hypothyroidism.

4. Conclusion

To our knowledge this is the first case report on simultaneous occurrence of TTP and severe hypothyroidism within 1 month of sunitinib treatment. This raises the hypothesis to look for early clinical signs of hypothyroidism, as early as 2 weeks after initiating therapy. Oncologists should instruct their patients about alarming symptoms and have high clinical suspicion for such rare adverse events. We highly suggest closer monitoring of TSH, kidney function, blood pressure, and platelet count in all patients treated with sunitinib or anti-VEGF therapy.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

References


